Crinetics Pharmaceuticals Inc
$ 44.52
1.67%
24 Feb - close price
- Market Cap 4,488,994,000 USD
- Current Price $ 44.52
- High / Low $ 44.57 / 43.42
- Stock P/E N/A
- Book Value 11.34
- EPS -4.53
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.44 %
- 52 Week High 57.99
- 52 Week Low 24.10
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Analyst Target Price
$85.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.9 | -1.01 | -0.94 | -0.85 | -0.84 |
| Estimated EPS | -1.25 | -1.1 | -0.9523 | -0.8919 | -0.91 | -0.86 | -0.81 | -0.86 | -0.86 | -0.86 | -0.81 | -0.82 |
| Surprise | -0.13 | -0.13 | -0.0877 | 0.0119 | -0.05 | -0.08 | -0.12 | -0.04 | -0.15 | -0.08 | -0.04 | -0.02 |
| Surprise Percentage | -10.4% | -11.8182% | -9.2093% | 1.3342% | -5.4945% | -9.3023% | -14.8148% | -4.6512% | -17.4419% | -9.3023% | -4.9383% | -2.439% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRNX
2026-02-23 05:19:31
Crinetics Pharmaceuticals (CRNX) has seen a shift in its investment story due to positive Phase 2 data for congenital adrenal hyperplasia (CAH) with Atumelnant and early commercial success of its FDA-approved oral acromegaly therapy, Palsonify. These developments are strengthening analyst confidence in the company's pipeline and its potential to serve rare disease patients. The article discusses how this positive data could reshape Crinetics' growth profile and investment narrative, while also noting the importance of Palsonify's uptake in funding future pipeline developments.
2026-02-23 04:51:20
Crinetics Pharmaceuticals recently released positive Phase 2 data for congenital adrenal hyperplasia and reported early commercial success for its FDA-approved drug, Palsonify. These developments are strengthening analyst confidence in the company's pipeline and its potential to address rare disease patient needs. The article suggests these results could significantly reshape Crinetics' investment narrative and its long-term growth prospects.
2026-02-20 09:27:26
Aberdeen Group plc significantly increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 21.3% in Q3, now holding 339,949 shares valued at $14.16 million, representing about 0.36% of the company. Institutional investors collectively own 98.51% of Crinetics Pharmaceuticals. Analyst sentiment for CRNX is a "Moderate Buy" with a consensus target price of $75.78, despite some mixed ratings.
2026-02-19 11:27:26
Analysts are bullish on Crinetics Pharmaceuticals (CRNX) following positive clinical trial results for its congenital adrenal hyperplasia treatment and strong initial sales for its FDA-approved acromegaly drug, Palsonify. Stifel, Piper Sandler, and Goldman Sachs have all maintained or upgraded their ratings and raised price targets for CRNX, citing successful Phase 2 trial outcomes and better-than-expected fourth-quarter performance. The company specializes in developing novel therapeutics for rare endocrine diseases.
2026-02-19 08:56:52
Crinetics Pharmaceuticals (CRNX) is anticipated to release its Q4 2025 earnings after market close on Thursday, February 26, 2026, with analysts forecasting an EPS of ($1.35) and revenue of $4.323 million. The stock recently opened at $43.45, and while analyst ratings are mixed, the average sentiment is a "Moderate Buy" with a target price of $75.78. Insider Isabel Kalofonos recently sold 2,500 shares, and institutional investors hold approximately 98.5% of the company's stock.
2026-02-19 00:56:52
Analysts are expressing strong confidence in Crinetics Pharmaceuticals Inc. (CRNX) following positive developments in its clinical trials and drug launches. Stifel raised its price target to $84, Piper Sandler maintained a Buy rating with a $97 target, and Goldman Sachs upgraded its rating to Buy based on encouraging Phase 2 results for a congenital adrenal hyperplasia treatment. The company is actively developing novel therapeutics for rare endocrine diseases.
